Showing results (401-410 of 447) with videos related to
Sort By:
Pageof 45
Human Mutation|August 27, 2019
Tubular aggregate myopathy and Stormorken syndrome: Mutation spectrum and genotype/phenotype correlationGilles Morin, Valérie Biancalana, Andoni Echaniz-Laguna, et al.Anticancer Research|February 13, 2010
Blue light is phototoxic for B16F10 murine melanoma and bovine endothelial cell lines by direct cytocidal effectAgnes Sparsa, Karine Faucher, Vincent Sol, et al.Journal of Neuropathology and Experimental Neurology|July 27, 2025
Autophagy impairment is associated with enhanced satellite cell activation in muscle biopsies from younger late-onset Pompe disease patientsGianmarco Severa, Sultan Bastu, Giovanni Umberto Borin, et al.Clinical Endocrinology|April 26, 2022
Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 monthHamza Benderradji, Elise Vernotte, Gustave Soto Ares, et al.Brain Pathology (Zurich, Switzerland)|October 5, 2017
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular featuresFranck Bielle, Anna-Luisa Di Stefano, David Meyronet, et al.Acta Neuropathologica Communications|July 21, 2016
Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutationAnthony Papegaey, Sabiha Eddarkaoui, Vincent Deramecourt, et al.Small (Weinheim an Der Bergstrasse, Germany)|September 29, 2025
Novel Diffuse Midline Glioma-on-Chip Recapitulating Tumor Biophysical Microenvironment to Assess the Heterogeneity of Response to TherapiesLisa Terrassoux, Calypso Hazard, Agathe Laratte, et al.Neuro-Oncology|December 14, 2019
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasRomain Appay, Caroline Dehais, Claude-Alain Maurage, et al.Therapie|December 15, 2010
[Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?]Luc Buée, David Blum, Stéphanie Bombois, et al.European Journal of Cancer (Oxford, England : 1990)|December 30, 2023
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trialEmilie Le Rhun, Thierry Gorlia, Jörg Felsberg, et al.Pageof 45